SCHEMBL2353733

SCHEMBL2353733

CC(C)(C)OC(=O)NCC1(O)CCN(C(=O)OCC2c3ccccc3-c3ccccc32)CC1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.42
KMT2A Q03164 2/20 0.40
MDM2 Q00987 1/20 0.39
KDM4E B2RXH2 1/20 0.39
PKM P14618 1/20 0.39
CASP1 P29466 1/20 0.38
EPHX2 P34913 1/20 0.38
KDM1A O60341 1/20 0.38
HTR1D P28221 1/20 0.38
HTR1B P28222 1/20 0.38
MDM4 O15151 1/20 0.38
TP53 P04637 1/20 0.38
NPFFR1 Q9GZQ6 1/20 0.38
NPFFR2 Q9Y5X5 1/20 0.38
DRD2 P14416 1/20 0.37
PDK2 Q15119 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19183444 0.89 KDM1A (0.46) BACE1KMT2AKDM1ANPFFR1NPFFR2
SCHEMBL29192643 0.85 PDK2 (0.40) BACE1KMT2AKDM4EPKMCASP1
SCHEMBL1764254 0.83 BACE1 (0.43) BACE1KMT2AMDM2KDM4EPKM
SCHEMBL20209336 0.82 KDM4E (0.56) BACE1KDM4EPKMKDM1ADRD2
SCHEMBL2771805 0.82 BACE1 (0.41) BACE1KMT2AMDM2KDM4EPKM
SCHEMBL31210310 0.81 BACE1 (0.51) BACE1KMT2AKDM4EPKMPDK2
SCHEMBL18926981 0.81 BACE1 (0.51) BACE1KMT2AKDM4EPKMPDK2
SCHEMBL5352770 0.81 KDM1A (0.53) KMT2AKDM1ANPFFR1NPFFR2
SCHEMBL2771592 0.81 BACE1 (0.40) BACE1KMT2AMDM2CASP1EPHX2
SCHEMBL4807050 0.80 DRD2 (0.55) KMT2ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2536283-B1 PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF TRANSTECH PHARMA LLC (US) 2015-07-29 EP disclosed
US-9045461-B2 Phenyl-heteroaryl derivatives and methods of use thereof TRANSTECH PHARMA, LLC (US) 2015-06-02 US disclosed
US-20140206660-A1 Phenyl-Heteroaryl Derivatives and Methods of Use Thereof TRANSTECH PHARMA, LLC (US) 2014-07-24 US disclosed
US-8741900-B2 Phenyl-heteroaryl derivatives and methods of use thereof TRANSTECH PHARMA, LLC (US) 2014-06-03 US disclosed
US-20130197007-A1 Phenyl-Heteroaryl Derivatives and Methods of Use Thereof TRANSTECH PHARMA, INC. (US) 2013-08-01 US disclosed
US-8431575-B2 Phenyl-heteroaryl derivatives and methods of use thereof TRANSTECH PHARMA, INC. (US) 2013-04-30 US disclosed
EP-2536283-A1 PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF TransTech Pharma, Inc (US) 2012-12-26 EP disclosed
US-20110230458-A1 PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF TRANSTECH PHARMA, INC. (US) 2011-09-22 US disclosed
WO-2011103091-A1 PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF TRANSTECH PHARMA, INC. (US) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140206660-A1 Phenyl-Heteroaryl Derivatives and Methods of Use Thereof AGER, NOD2, GPBAR1 BACE1 1094/4885KMT2A 4202/4885MDM2 226/4885
US-20110230458-A1 PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF AGER, PSEN2, PSEN1 BACE1 13/4885KMT2A 4080/4885MDM2 219/4885
US-20130197007-A1 Phenyl-Heteroaryl Derivatives and Methods of Use Thereof AGER, PSEN2, PSEN1 BACE1 13/4885KMT2A 4080/4885MDM2 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.